These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 38140952)

  • 1. Protein degraders - from thalidomide to new PROTACs.
    Ito T
    J Biochem; 2024 Apr; 175(5):507-519. PubMed ID: 38140952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homo-PROTACs for the Chemical Knockdown of Cereblon.
    Steinebach C; Lindner S; Udeshi ND; Mani DC; Kehm H; Köpff S; Carr SA; Gütschow M; Krönke J
    ACS Chem Biol; 2018 Sep; 13(9):2771-2782. PubMed ID: 30118587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs.
    Lindner S; Steinebach C; Kehm H; Mangold M; Gütschow M; Krönke J
    J Vis Exp; 2019 May; (147):. PubMed ID: 31157769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of a Cereblon construct for crystallographic and biophysical studies of protein degraders.
    Kroupova A; Spiteri VA; Rutter ZJ; Furihata H; Darren D; Ramachandran S; Chakraborti S; Haubrich K; Pethe J; Gonzales D; Wijaya AJ; Rodriguez-Rios M; Sturbaut M; Lynch DM; Farnaby W; Nakasone MA; Zollman D; Ciulli A
    Nat Commun; 2024 Oct; 15(1):8885. PubMed ID: 39406745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders.
    Yang K; Zhao Y; Nie X; Wu H; Wang B; Almodovar-Rivera CM; Xie H; Tang W
    Cell Chem Biol; 2020 Jul; 27(7):866-876.e8. PubMed ID: 32413286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates.
    Shimizu N; Asatsuma-Okumura T; Yamamoto J; Yamaguchi Y; Handa H; Ito T
    Commun Biol; 2021 Nov; 4(1):1277. PubMed ID: 34764413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IKZF2 Degradation: It's Time to Take into Account it When Designing Cereblon-Based PROTACs.
    Li M
    Chembiochem; 2024 Aug; 25(16):e202400365. PubMed ID: 38802326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders.
    Yamamoto J; Ito T; Yamaguchi Y; Handa H
    Chem Soc Rev; 2022 Aug; 51(15):6234-6250. PubMed ID: 35796627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Substituted Phenyl Dihydrouracil as the Novel Achiral Cereblon Ligands for Targeted Protein Degradation.
    Xie H; Li C; Tang H; Tandon I; Liao J; Roberts BL; Zhao Y; Tang W
    J Med Chem; 2023 Feb; 66(4):2904-2917. PubMed ID: 36749666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms of thalidomide and its derivatives.
    Ito T; Handa H
    Proc Jpn Acad Ser B Phys Biol Sci; 2020; 96(6):189-203. PubMed ID: 32522938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of novel cereblon modulators and their target molecules].
    Ito T
    Rinsho Ketsueki; 2022; 63(6):573-579. PubMed ID: 35831190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology.
    Ito T; Yamaguchi Y; Handa H
    Cell Chem Biol; 2021 Jul; 28(7):987-999. PubMed ID: 34033753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide.
    Fischer ES; Böhm K; Lydeard JR; Yang H; Stadler MB; Cavadini S; Nagel J; Serluca F; Acker V; Lingaraju GM; Tichkule RB; Schebesta M; Forrester WC; Schirle M; Hassiepen U; Ottl J; Hild M; Beckwith RE; Harper JW; Jenkins JL; Thomä NH
    Nature; 2014 Aug; 512(7512):49-53. PubMed ID: 25043012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
    Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G
    FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leveraging Ligand Affinity and Properties: Discovery of Novel Benzamide-Type Cereblon Binders for the Design of PROTACs.
    Steinebach C; Bricelj A; Murgai A; Sosič I; Bischof L; Ng YLD; Heim C; Maiwald S; Proj M; Voget R; Feller F; Košmrlj J; Sapozhnikova V; Schmidt A; Zuleeg MR; Lemnitzer P; Mertins P; Hansen FK; Gütschow M; Krönke J; Hartmann MD
    J Med Chem; 2023 Nov; 66(21):14513-14543. PubMed ID: 37902300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon.
    Akuffo AA; Alontaga AY; Metcalf R; Beatty MS; Becker A; McDaniel JM; Hesterberg RS; Goodheart WE; Gunawan S; Ayaz M; Yang Y; Karim MR; Orobello ME; Daniel K; Guida W; Yoder JA; Rajadhyaksha AM; Schönbrunn E; Lawrence HR; Lawrence NJ; Epling-Burnette PK
    J Biol Chem; 2018 Apr; 293(16):6187-6200. PubMed ID: 29449372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation.
    Liu H; Ding X; Liu L; Mi Q; Zhao Q; Shao Y; Ren C; Chen J; Kong Y; Qiu X; Elvassore N; Yang X; Yin Q; Jiang B
    Eur J Med Chem; 2021 Nov; 223():113645. PubMed ID: 34217059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strengthening Molecular Glues: Design Strategies for Improving Thalidomide Analogs as Cereblon Effectors and Anticancer Agents.
    Nutt MJ; Stewart SG
    Drug Discov Today; 2024 Jun; 29(6):104010. PubMed ID: 38704021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From Thalidomide to Rational Molecular Glue Design for Targeted Protein Degradation.
    Oleinikovas V; Gainza P; Ryckmans T; Fasching B; Thomä NH
    Annu Rev Pharmacol Toxicol; 2024 Jan; 64():291-312. PubMed ID: 37585660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase.
    Petzold G; Fischer ES; Thomä NH
    Nature; 2016 Apr; 532(7597):127-30. PubMed ID: 26909574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.